My watch list
my.bionity.com  
Login  
29 avenue du Sidobre
81106 Castres
France
Tel.
+33563516800
Fax
+33563516875

Company Portrait

Pierre Fabre Médicament is the 2nd largest independent French pharmaceutical laboratory, and orients its development on specifically targeted therapeutic lines. Investment in research has resulted in the discovery of new molecules, and this effort has enabled the firm to reinforce and emphasise its world-wide development.

A rigorous approach based on our pharmaceutical culture. Europe's No. 1 dermo-cosmetic laboratory for pharmacy products; 3.8 % of our turnover is dedicated to research and development. Pierre Fabre Dermo-Cosmétique is a privileged partner for dermatologists and pharmacists.

Pierre Fabre Santé, Pierre Fabre ORAL CARE and Plants & Medicines design, manufacture and distribute prevention and public health drugs, whilst concentrating their efforts on specific therapeutic lines.

Focus: Manufacturer

Industrial Sectors

  • Pharma

Watchlist

This is where you can add this company to your personal favourites

More about Laboratoires Pierre Fabre
  • News

    Olivier Bohuon Appointed Chief Executive Officer of Pierre Fabre SA

    During its first meeting, the Board of Directors of Pierre Fabre SA chaired by Mr. Pierre Fabre appointed Olivier Bohuon as the company's Chief Executive Officer. Olivier Bohuon, 51, has until now been the executive vice-president of Abbott Corporation and president of its pharmaceutics di ... more

    LibraGen signs partnership agreement with Pierre Fabre Medicament R&D

    LibraGen announced that it has signed a partnership agreement with the R&D department of Pierre Fabre Medicament, France's second largest independent pharmaceutical company. Under the terms of the agreement, LibraGen will use enzymatic technologies to optimize the synthesis of a molecule wh ... more

  • Companies

    Laboratoires Pierre Fabre SA

    Pierre Fabre Médicament is the 2nd largest independent French pharmaceutical laboratory, and orients its development on specifically targeted therapeutic lines. Investment in research has resulted in the discovery of new molecules, and this effort has enabled the firm to reinforce and empha ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE